Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Preferred Stock Liabilities: 2017

  • Arcus Biosciences' Preferred Stock Liabilities was N/A to $226.2 million in Q4 2017 from the same period last year, while for Dec 2017 it was $226.2 million, marking a year-over-year change of. This contributed to the annual value of $226.2 million for FY2017, which is N/A change from last year.
  • Latest data reveals that Arcus Biosciences reported Preferred Stock Liabilities of $226.2 million as of Q4 2017.
  • Over the past 5 years, Arcus Biosciences' Preferred Stock Liabilities peaked at $226.2 million during Q4 2017, and registered a low of $226.2 million during Q4 2017.
  • Over the past 1 years, Arcus Biosciences' median Preferred Stock Liabilities value was $226.2 million (recorded in 2017), while the average stood at $226.2 million.